Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit Technology

This article was originally published in The Gray Sheet

Executive Summary

Ophthalmic excimer laser maker completes acquisition of Autonomous Technologies for cash and stock valued at $224 mil. The amount is more than double the previously estimated value of $86.6 mil. when the deal was announced in October 1998, due to recent gains in Summit's stock market value ("The Gray Sheet" Nov. 9, 1998, p. 7). Autonomous shareholders will receive .727 shares of Summit common stock and $3.04 in cash for each of their shares. The deal will total about 11.2 mil. Summit shares and $46.8 mil. in cash

You may also be interested in...



Summit Technology

Ophthalmic excimer laser firm's secondary offering of 4 mil. shares is outlined in a registration statement filed with the Securities and Exchange Commission. Net proceeds will be used to fund the ongoing roll-out of the LADARVision tracker-assisted ophthalmic excimer laser system and for general corporate purposes. The system received PMA approval from FDA in November 1998 for treatment of mild to moderate nearsightedness with or without astigmatism. Acquired with Autonomous Technologies in April, the product's market debut was delayed until completion of the merger on account of patent litigation concerns (1"The Gray Sheet" May 3, In Brief). The offering is being managed by Hambrecht & Quist LLC, U.S. Bancorp Piper Jaffray and Dain Rauscher Wessels, which have an overallotment option of 600,000 additional shares

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel